retatrutide type 2 diabetes trial nct Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA Lilly's Retatrutide shows promise in

It helps neutralize free radicals (a highly volatile group of atoms which are formed when oxygen interacts with certain molecules) which damage other cells within the body

Evidence and Guidance Allulose, a rare low-calorie sugar, has attracted interest for its potential metabolic benefits, particularly amongst individuals managing diabetes or taking glucagon-like peptide-1 (GLP-1) receptor agonist medications

Both the LEADER (liraglutide) and SUSTAIN-6 (subcutaneous semaglutide) trials reported significant reductions in the primary outcome (incidence of MACE)

No, maintenance sessions and good skincare habits are needed to maintain the glow